Class III β-Tubulin Overexpression Induces Chemoresistance to Eribulin in a Leiomyosarcoma Cell Line

Eribulin is a new drug to treat soft tissue sarcoma (STS) that exerts antitumor activity by binding to microtubules. The prognosis of STS is poor, and eribulin is expected to improve the treatment outcome. We observed several cases that exhibited resistance to eribulin and developed an eribulin-resi...

Full description

Saved in:
Bibliographic Details
Main Authors: Kenichiro Yahiro, Yoshihiro Matsumoto, Jun-ichi Fukushi, Ken-ichi Kawaguchi, Makoto Endo, Nokitaka Setsu, Keiichiro IIda, Suguru Fukushima, Makoto Nakagawa, Atsushi Kimura, Yoshinao Oda, Yasuharu Nakashima
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:Analytical Cellular Pathology
Online Access:http://dx.doi.org/10.1155/2018/8987568
Tags: Add Tag
No Tags, Be the first to tag this record!